Andrew Hollands

Andrew Hollands is a highly experienced professional in the field of biological sciences, currently serving as the Director of Early Research at Inhibrx, Inc., where responsibilities include the evaluation and early development of antibody-based therapeutics across various disease areas. With a strong foundation in managing research groups focused on oncology and infectious diseases, Andrew secured over $8 million in non-dilutive funding for biotherapeutic programs. Previous roles include postdoctoral research at the University of California San Diego and the University of Wollongong, along with advisory work for the FAST Biotech Startup Accelerator. Andrew holds a Ph.D. and Bachelor’s degrees in Biological Sciences from the University of Wollongong, complemented by a study abroad experience at North Carolina State University.